Incyte Corp. (INCY) Stock Hammered on Discontinuation of Pancreatic Cancer Treatment
November 29, 2015 at 19:00 PM EST
Shares of Incyte Corp. (INCY) were down -10.56 or -14.60 percent to $61.75 per share in Thursday's premarket after the company reported better than expected earnings and revenue for the fourth quarter, but also announced it would discontinue its treatment of pancreatic cancer after an interim analysis failed to indicate sufficient efficacy. Incyte Corp. shares ... READ MORE Read the rest of Incyte Corp. (INCY) Stock Hammered on Discontinuation of Pancreatic Cancer Treatment at InvestorGuide.com .
